National Biosafety Month 2017: Sharps Safety and Exposure Response

During 2017's National Biosafety Month, you are encouraged to focus attention on biosafety policies, practices and procedures. Investigators and laboratory managers should raise biosafety awareness, discuss the importance of safety, and seek input on ways to strengthen biosafety practices and procedures in their labs. This year, EH&S is focusing on sharps safety in research and exposure response.

Chemotherapy & Hazardous Drugs

Drugs are classified as hazardous if they may cause cancer, developmental or reproductive toxicity or harm to organs at low doses. They include drugs used for cancer chemotherapy (also called antineoplastics), antiviral drugs, hormones, some bioengineered drugs and other various drugs. To determine if a drug is classified as hazardous check the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings (2014).

Clinical Trials

Human gene transfer and all other research involving recombinant or synthetic nucleic acids in human research participants requires review and approval by the UW Institutional Biosafety Committee (IBC) if it is sponsored by or conducted at the University of Washington. Studies involving deliberate transfer of genes into human research participants (human gene transfer) via either of the following are covered by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules Section III-C and require review by the UW IBC: